e-learning
resources
Vienna 2012
Wednesday, 05.09.2012
Prevalences and characterstics of obstructive airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Distribution of a COPD population based on the GOLD assessment framework
G. Nadeau, P.W. Jones, L. Adamek, M. Small (Uxbridge, , Macclesfield, United Kingdom)
Source:
Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease
Session:
Prevalences and characterstics of obstructive airway disease
Session type:
Poster Discussion
Number:
4748
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Nadeau, P.W. Jones, L. Adamek, M. Small (Uxbridge, , Macclesfield, United Kingdom). Distribution of a COPD population based on the GOLD assessment framework. Eur Respir J 2012; 40: Suppl. 56, 4748
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Distribution of COPD patients in the GOLD assessment framework by exacerbations
Source: Annual Congress 2012 - COPD epidemiology
Year: 2012
The distribution of COPD in general practice using three different GOLD classification
Source: International Congress 2018 – COPD around the world
Year: 2018
The distribution of COPD in UK general practice using the new GOLD classification
Source: Eur Respir J 2014; 43: 993-1002
Year: 2014
Stability of the exacerbation pattern defined by GOLD 2017 in a real-world COPD population
Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Year: 2017
Combined COPD assessment using the new GOLD guidelines
Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD
Year: 2012
Validation of non-spirometric predictors of COPD to the GOLD stage classification
Source: Eur Respir J 2002; 20: Suppl. 38, 123s
Year: 2002
Validation of the GOLD 2017 classification in a Chinese COPD cohort
Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Year: 2017
Implementation of the GOLD 2017 disease classification in a real-life COPD cohort
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018
Distribution and significance of GOLD 2011 disease severity classification in patients with COPD in China: A national cross-sectional survey
Source: Annual Congress 2013 –COPD: acute exacerbations and others
Year: 2013
Combined assessment according to the new GOLD guidelines and its relation to outcome in COPD
Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD
Year: 2012
Prediction of the clinical course of COPD using the old and the new GOLD classification
Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD
Year: 2012
The distribution of COPD in UK general practice using the 2017 GOLD classification
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017
Population impact of different definitions of COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 201s
Year: 2001
FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts
Source: Eur Respir J 2013; 42: 1391-1401
Year: 2013
Population based study on the prevalence of COPD by spirometric criteria
Source: Annual Congress 2010 - Prevalence and incidence of asthma and COPD
Year: 2010
GOLD assessment of COPD patients: Impact of symptoms assessment choice
Source: Annual Congress 2012 - GOLD guidelines 2011: new assessment of COPD
Year: 2012
Rehabilitation programs in patients in different severity stage of COPD (GOLD II-to-IV): analysis of the results
Source: Eur Respir J 2005; 26: Suppl. 49, 69s
Year: 2005
Efficacy of revefenacin based on GOLD 2017 categories: reanalysis of phase 3 data in patients with COPD
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Heterogeneity of group D in the new GOLD classification of COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Metabolic and cardiovascular comorbidity in COPD patients classified using the GOLD 2011 assessment framework
Source: Annual Congress 2012 - COPD epidemiology
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept